Pulmonx, a maker of medical devices and technologies for pulmonary disorders, has named Michael A. Baker as president and CEO.
Baker’s career includes assignments with ArthroCare Corporation, where he served as the president and CEO for over 11 years, and with Medtronic, where he served for over 8 years in executive and general management assignments in both the United States and Europe.
Pulmonx is venture funded by Montreux Ventures, MedVenture Associates, DeNovo Ventures, Latterell Ventures, Covidien Ventures and Posco Bioventures and recently received FDA marketing clearance for the Chartis System, an assessment tool which allows physicians to make regional assessments of lung function, including quantifying inter-lobar airflow in the lungs, known as collateral ventilation. Pulmonx intends to begin international commercialisation of the Chartis system as soon as it receives the CE mark.
Pulmonx recently acquired Emphasys Medical, which added Emphasys’ Zephyr family of endobronchial valves for Endobronchial Lung Volume Reduction (ELVR) to the company’s proprietary portfolio of diagnostic and therapeutic products.
The Zephyr endobronchial valves are already CE marked and commercially available in many countries around the world.
